Summary by Futu AI
WuXi Biologics Technologies Co., Ltd. submitted the disclosure report the day after on September 25, 2024, disclosing its share repurchase situation. According to the report, the company repurchased 1,325,500 ordinary shares on September 25, 2024, at a repurchase price ranging from HKD 12.86 to HKD 13.12 per share, with a total payment amount of HKD 17,257,880. The repurchased shares will be proposed for cancellation, not held as treasury shares. After the repurchase, the total number of issued shares of WuXi Biologics remained at 4,154,186,796 shares. The company confirmed that the repurchase action had been formally authorized and approved by the board of directors, and complied with all applicable listing rules, laws, and other regulatory requirements. The resolution authorizing the repurchase was passed on June 19, 2024. According to the authorization, the company could repurchase a total of 415,129,694 shares. As of the reporting date, 43,698,500 shares have been repurchased, accounting for 1.0526% of the issued shares. After the repurchase, the company will enter a blackout period for one month, until October 25, 2024.
